Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Five years on, 3.9 million people in the developing world have access to HIV treatment dolutegravir, thanks to access-oriented voluntary licensing agreements
Innovative licensing agreements continue to provide access to dolutegravir in an unprecedented timeframe
-
ViiV Healthcare submits regulatory application to European Medicines Agency for investigational cabotegravir to be used in combination with rilpivirine as the first monthly, injectable treatment for HIV
The marketing application is based on phase III ATLAS and FLAIR trials in which the regimen showed similar efficacy to daily, 3-drug one.
-
ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance
ViiV - GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir & lamivudine continues to demonstrate high efficacy rates
-
ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection
International AIDS Society Conference on HIV Science demonstrate non-inferior efficacy of Dovato▼ in virally suppressed adults with HIV
-
GSK delivers sales and earnings growth in Q2 2019
Total EPS 19.5p, +>100% AER, +>100% CER; Adjusted EPS 30.5p +9% AER, +4% CER
-
GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors
GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors
-
ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019
Week 96 data from the BRIGHTE study of fostemsavir continue to show improvement in virologic suppression and immunologic response
-
IAS 2019: ViiV Healthcare showcasing innovation in HIV science
challenging the current treatment paradigm and investigating new options to meet the evolving needs of people living with HIV
-
GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA (niraparib) for patients with ovarian cancer in the first line maintenance setting
Niraparib demonstrates significant improvement in progression free survival for women regardless of their biomarker status
-
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen
Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019).
-
GSK welcomes the UK trial of subscription-style payment system for pharma companies to incentivise creation of new antibiotics
GSK welcomes the UK trial of subscription-style payment system for pharma companies to incentivise creation of new antibiotics
-
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice
The long-acting injectable regimen has been granted Priority Review status by the FDA, with a target approval date set for December 29, 2019
-
GSK announces phase III start for its anti GM-CSF antibody, otilimab, in patients with rheumatoid arthritis (RA)
First phase III programme in RA to include comparisons with current treatments across all studies in a range of RA patients.
-
ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection
Dovato achieved non-inferior efficacy compared to a dolutegravir-based, three-drug regimen through 48 weeks.
-
U.S. Food and Drug Administration accepts GSK’s application for ZEJULA (niraparib) in late stage ovarian cancer with priority review
TESARO, submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for ZEJULA (niraparib).
-
GSK joins forces with the University of California to advance genomic research and improve drug discovery
New ‘Laboratory for Genomics Research’ unites CRISPR pioneers with industry expertise to help unravel mysteries of the human genome
-
GSK announces data on anti-BCMA antibody-drug conjugate in patients with relapsed/refractory multiple myeloma to be presented at European Hematology Association (EHA) Congress
GSK today announced new data on belantamab mafodotin will be presented at the 24th Congress of the European Hematology Association.
-
Nucala (mepolizumab) gains FDA approval for two new self-administration options
GSK today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab)
-
Nucala (mepolizumab) receives positive CHMP opinion for new self-administration options
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion.
-
GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over
Shingrix is a recombinant subunit adjuvanted vaccine given intramuscularly in two doses.
